The Stunning Golden Parachutes of Juno's $9B Celgene Deal
Juno's Hans Bishop will take home $287M after Celgene acquired his company. Source: BioSpace
Boston's Intarcia Pink Slips 60 Employees, Terminates Two Late-Stage Trials
A tipster told BioSpace that the layoffs were initially announced by Intarcia CEO Kurt Graves on Jan. 31. Source: BioSpace
GSK, Reckitt are the Only Suitors for Pfizer's $20B Consumer Health Biz
Companies including Sanofi, J&J, Nestle have dropped out. Source: BioSpace
The 3 Small CRISPR Biotechs That Could Cure 10,000 Diseases
A look at three small biotech companies that appear to be leading the CRISPR race. Source: BioSpace
3 High-Risk Biotechs That Could Pop or Drop in 2018
A look at three biotech companies that face make-or-break catalysts this year. Source: BioSpace
Suitors Take Note as Bay Area's Nektar May Be Up for Sale
Nektar is reportedly exploring various strategic options, including a possible sale, partnerships or licensing agreements. Source: BioSpace
EyeGate Implodes as Eye Drug Flunks Phase II Test
EGP-437 demonstrated better clinical performance than vehicle control but did not meet its co-primary endpoints. Source: BioSpace
Mysterious Biotech Unicorn Moderna Nabs Another $500M, Is Now Worth $7B
One can only hope that Moderna Therapeutics can live up to the hype, both scientifically and financially. Source: BioSpace
M&A Chatter Swirls Over Amgen's $70B Cashpile
Amgen reported its fourth-quarter financials yesterday, but in anticipation of this year's hot merger-and-acquisition market, a lot of focus has been on the company's considerable available cash. Source: BioSpace
Array BioPharma Slaps $192M Lawsuit on AstraZeneca Over Cancer Drug Royalties
AstraZeneca did not immediately respond to a request for comment. Source: BioSpace
- Go to the previous page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- …
- 288
- Go to the next page